

## References

1. de Jong MD, Hien TT. Avian influenza A (H5N1). *J Clin Virol*. 2006;35:2–13.
2. World Health Organization. Epidemic and pandemic alert and response: confirmed human cases of avian influenza A (H5N1). [cited 2007 Apr 23]. Available from [http://www.who.int/csr/disease/avian\\_influenza/country/en/index.html](http://www.who.int/csr/disease/avian_influenza/country/en/index.html)
3. Dinh PN, Long HT, Tien NTK, Hien NT, Mai LTQ, Phong LH, et al. Risk factors for human infection with avian influenza A H5N1, Vietnam, 2004. *Emerg Infect Dis*. 2006;12:1841–7.
4. Bonneux L, van Damme W. An iatrogenic pandemic of panic. *BMJ*. 2006;332:786–8.
5. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. *Ann Intern Med*. 1993;118:201–10.

Address for correspondence: Janice Luisa Lukrafka, Medical Sciences Postgraduate Program, Universidade Federal do Rio Grande do Sul, 2400 Ramiro Barcelos St, 90035-903 Porto Alegre, RS Brazil; email: [jlukrafka@pop.com.br](mailto:jlukrafka@pop.com.br)

**In Response:** Lukrafka et al. (1) warn against the dangers of overfitting a regression model when the number of outcomes is <10 per variable, “which could result in imprecise estimates or spurious associations.” This warning is valid, but it is equally important to consider the relative merits of multiple analysis options given the data available, the difficulties in collecting the data, and the objective of the study. The objective of our study (2) was to explore possible risk factors for human infection with influenza A (H5N1) rather than to test an explicit a priori hypothesis or to obtain precise estimates of risk. We were limited to a finite number of cases, and had we slavishly followed criteria to avoid overfitting, we would not have run a regression model at all because we could have included only 2 variables, for which a stratified analysis would

have been preferable. The regression model was run to confirm that the variables identified in the bivariate analysis retained their importance in the context of other variables; it was not intended to confirm or refute an a priori hypothesis, to be a predictive model, or to obtain precise and adjusted measures of risk. Despite the sample size limitations, we felt that looking at independence in a multivariable analysis was still valuable.

We explicitly acknowledge the limitations imposed by a small study size and were cautious in our interpretation, stating that the findings are the “basis for formulating new hypotheses.” The wide confidence intervals clearly indicate the low level of precision. The 3 variables in the final regression model were all statistically significant in bivariate analysis, and we do not believe they are spurious associations arising solely from an overfitted regression model.

**Peter Horby\***

\*National Institute for Infectious and Tropical Diseases, Hanoi, Vietnam

## References

1. Lukrafka JL, Zavascki AP, Barcellos N, Fuchs SC. Determining risk factors for infection with influenza A (H5N1) [letter]. *Emerg Infect Dis*. 2007;13:955–56.
2. Dinh PN, Long HT, Tien NTK, Hien NT, Mai LTQ, Phong LH, et al. Risk factors for human infection with avian influenza A H5N1, Vietnam, 2004. *Emerg Infect Dis*. 2006;12:1841–7.

Address for correspondence: Peter Horby, National Institute for Infectious and Tropical Diseases, 78 Giai Phong St, Hanoi, Vietnam; email: [peter.horby@gmail.com](mailto:peter.horby@gmail.com)

All material published in *Emerging Infectious Diseases* is in the public domain and may be used and reprinted without special permission; proper citation, however, is required.

## *Ilheus Virus Isolate from a Human, Ecuador*

**To the Editor:** *Ilheus virus* (ILHV) (genus *Flavivirus* in the Ntaya antigenic complex) is most closely related to *Rocio virus*. However, antibodies produced during ILHV infection cross-react in serologic assays to other flavivirus antigens, and ILHV was originally classified in the Japanese encephalitis antigenic complex (1–3). ILHV is transmitted in an enzootic cycle between birds and mosquitoes. Since the first isolation of ILHV from a pool of *Aedes* spp. and *Psorophora* spp. mosquitoes collected in 1944 at Ilheus City, on the eastern coast of Brazil (4), isolates have been obtained in Central and South America and Trinidad, primarily from *Psorophora ferox* mosquitoes (5,6). ILHV is not associated with epidemic disease and has been only sporadically isolated from humans (5,7–9). The clinical spectrum of human infections documented by virus isolation ranges from asymptomatic to signs of central nervous system involvement suggestive of encephalitis. Most commonly, patients exhibit a mild febrile illness accompanied by headache, myalgia, arthralgia, and photophobia, symptoms that may result in clinical diagnosis of dengue, Saint Louis encephalitis, yellow fever, or influenza (7). Laboratory diagnosis of ILHV infection may be difficult, unless a virus isolate can be obtained, because of the cross-reactivity in serologic assays to other flaviviruses that circulate in the same area, such as Rocio, dengue, yellow fever, and Saint Louis encephalitis viruses.

On March 1, 2004, after 4 days of symptoms, a 20-year-old male soldier stationed in Lorocachi, Ecuador, was admitted to the Hospital de la IV División del Ejército “Amazonas” in Puyo, Ecuador. Lorocachi is in the Amazonian province of Pastaza, of which Puyo is the capital. The patient

had fever, rash, epistaxis, headache, myalgia, retroocular pain, nausea, vomiting, jaundice, sore throat, and abdominal pain.

A blood specimen (containing isolate FSE800) was collected, and an acute-phase serum sample was processed for virus isolation in C6/36 (*Aedes albopictus*) and Vero cells. After 3 days, cytopathic effects were observed, and cells were screened by an immunofluorescence assay for reactivity against alphaviruses and flaviviruses by using polyclonal antibodies. The cells gave positive results with yellow fever, Saint Louis encephalitis, Rocio, and Ilheus antisera. Viral RNA was then extracted from the patient's acute-phase serum and cell supernatants and processed for virus sequencing. Amplification of an  $\approx$ 250-bp product by SyBRgreen real-time reverse transcriptase PCR and subsequent sequencing of the amplicon were conducted with the flavivirus consensus primers FU1 and cFD2 (2). Viruses were identified by BLAST search ([www.ncbi.nlm.nih.gov/blast](http://www.ncbi.nlm.nih.gov/blast)) and alignment to GenBank

sequences. FSE800 had 96% identity (182 of 188 bp) with the nonstructural (NS) 5 region of the original ILHV strain AY632539 (1). An ILHV original 1944 isolate used as positive control had 100% sequence identity with AY632539.

Limited sequence information is available in GenBank for ILHV outside of the conserved NS5 region. Therefore, further sequencing of the NS5 region using flavivirus consensus primers FU1 and cFD3 (2) and the complete envelope (E) gene region, based on the complete open reading frame ILHV nucleotide sequence AY632539 (1), was conducted on FSE800, as well as a low-passage original 1944 isolate (R. Tesh, University of Texas Medical Branch [UTMB]), 2 mosquito isolates from Iquitos, Peru (R. Tesh, UTMB), and 2 human isolates from Brazil (CDC) (8) (Figure). There was 100% sequence identity among the 2 Brazilian and 2 Peruvian isolates at both gene regions. In the NS5 region, there was 100% identity between Brazilian and original isolates; 95% identity between FSE800 and Brazilian-origi-

nal isolates; 98% identity between FSE800 and Peruvian isolates; and 96% identity between Peruvian and original-Brazilian isolates. At the protein level, 3 amino acid (aa) differences were found between FSE800 and original-Brazilian isolates, 2 between FSE800-Peruvian and original-Brazilian isolates (aa 3086, Lys-Gln; aa 3138, Ala-Val) and 1 between FSE800 and original-Brazilian-Peruvian isolates (aa 3309, Asp-Asn).

In the E gene region, there was 99.9% identity between original and Brazilian isolates; 95.1% and 95% identity between FSE800 and original and Brazilian isolates, respectively; 98.5% identity between FSE800 and Peruvian isolates; and 95.3% identity between Peruvian and original isolates. At the protein level, 2 aa differences were found between original-Brazilian and Peruvian-FSE800 isolates (aa 432, Ile-Thr; aa 652, Lys-Asn), 1 aa change only in Brazilian isolates (aa 570, His-Tyr), and 1 only in Peruvian isolates (aa 675, Asn-Ser). With the exception of the Ala-Val change, all were nonconservative changes. The effect of the amino acid changes has yet to be determined. However, nucleotide sequence comparison between the 6 ILHV isolates has shown that these gene regions are highly conserved geographically and temporally.

Ilheus virus is not usually associated with human disease, and human ILHV infections may not be correctly identified without a virus isolate because of the similar clinical symptoms and cross-reactivity in serologic assays to other flaviviruses. As laboratory surveillance is enhanced to monitor the emergence of West Nile virus in Central and South America, detection of ILHV and other flaviviruses may increase.

#### Acknowledgments

We thank Alfredo Huaman and Roxana Caceda for their expert serologic and isolation assistance, respectively; Robert Tesh for contribution of the 3 ILHV iso-




Figure. Phylogenetic analysis of the NS5 (A) and E gene (B) regions of 6 *Ilheus virus* (ILHV) isolates. The sequences were aligned in MegAlign (DNASTAR, Inc., Madison, WI, USA); the alignments were then analyzed by using the maximum parsimony method with 500 bootstrap replicates in the program MEGA 3.1 (10). *Rocio virus* (GenBank accession no. AY632542) was included as an outgroup in the analysis, based on the phylogram of Kuno and Chang (1). Bootstrap values, shown in **boldface** above the branch, are percentages derived from 500 samplings; branch lengths are shown below the branch. Scale bars show nucleotide changes. The sequences generated from our study were deposited in GenBank under accession nos. EF396941–EF396952.

lates; and Robert S. Lanciotti and Goro Kuno for technical assistance.

**Barbara W. Johnson,\*  
Cristopher Cruz,† Vidal  
Felices,† William R. Espinoza,‡  
Stephen Robert Manock,§  
Carolina Guevara,† James G.  
Olson,† and Tadeusz J. Kochel†**

\*Centers for Disease Control and Prevention, Fort Collins, Colorado, USA; †US Naval Medical Research Center Detachment, Lima, Peru; ‡Hospital de la IV División del Ejército "Amazonas," Puyo, Ecuador; and §Hospital Vozandes del Oriente, Shell, Ecuador

## References

1. Kuno G, Chang GJ. Biological transmission of arboviruses: reexamination of and new insights into components, mechanisms, and unique traits as well as their evolutionary trends. *Clin Microbiol Rev.* 2005;18:608–37.
2. Kuno G, Chang GJ, Tsuchiya KR, Karabatsos N, Cropp CB. Phylogeny of the genus *Flavivirus*. *J Virol.* 1998;72:73–83.
3. Monath TP, Heinz F. Flaviviruses. In: Knipe D, Howley P, editors. *Fields virology*. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 1996. p. 1043–125.
4. Laemmert H, Hughes T. The virus of Ilheus encephalitis: isolation, serological specificity and transmission. *J Immunol.* 1947;55:61–7.
5. Srihongse S, Johnson CM. The isolation of Ilheus virus from a man in Panama. *Am J Trop Med Hyg.* 1967;16:516–8.
6. Pinheiro F, Travassos da Rosa A. Ilheus fever. In: Beran G, Steel J, editors. *CRC handbook of zoonoses*. Boca Raton (FL): CRC Press; 1994. p. 210.
7. Figueiredo LT. The Brazilian flaviviruses. *Microbes Infect.* 2000;2:1643–9.
8. Nassar ES, Coimbra TL, Rocco IM, Pereira LE, Ferreira IB, de Souza LT, et al. Human disease caused by an arbovirus closely related to Ilheus virus: report of five cases. *Intervirology.* 1997;40:247–52.
9. Prias-Landinez E, Bernal-Cubides C, Morales-Alarcon A. Isolation of Ilheus virus from a man in Colombia. *Am J Trop Med Hyg.* 1968;17:112–4.
10. Kumar S, Tamura K, Nei M. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. *Brief Bioinform.* 2004;5:150–63.

Address for correspondence: Barbara W. Johnson, Arbovirus Diseases Branch, Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention, 3150 Rampart Rd, Fort Collins, CO 80521, USA; email: [bfj9@cdc.gov](mailto:bfj9@cdc.gov)



Search  
past Issues

**EID**  
*Online*  
[www.cdc.gov/eid](http://www.cdc.gov/eid)